CHM-1222

CHM-1222 is an investigational small molecule drug candidate currently in development by Chemia, a biotechnology company that utilizes an AI-driven platform to discover natural product-inspired therapeutics. The compound was identified through Chemia's proprietary discovery engine, which integrates machine learning with automated chemical synthesis to explore novel chemical spaces and optimize molecules derived from natural sources. While CHM-1222 is featured in the company's active development pipeline, specific details regarding its biological target, mechanism of action, and primary therapeutic indication have not been publicly disclosed. It represents part of Chemia's broader strategy to leverage computational chemistry to accelerate the transition from natural product discovery to clinical-ready candidates.